Other Events ·
InflaRx N.V. is assessing a broadened development and registrational strategy for ANCA-Associated Vasculitis (AAV) in…
IFRXInflaRx N.V.
InflaRx N.V. is assessing a broadened development and registrational strategy for ANCA-Associated Vasculitis (AAV) in Europe following the European Medicines Agency's (EMA) recommendation on June 26, 2026, to revoke the marketing authorization for Tavneos. The company intends to engage with the EMA regarding its anti-C5a antibody vilobelimab and next-generation oral C5aR inhibitor izicopan to determine the most efficient development pathway. InflaRx is a biotechnology company that develops therapies for inflammatory and autoimmune diseases.